This site is for U.S. Healthcare Professionals only.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Oral
Edoxaban
JCS 2025 | March 28-30, 2025
A history of falls and clinical outcomes in older adult patients with non-valvular atrial fibrillation from the ANAFIE Registry
Oral
Edoxaban
JCS 2025 | March 28-30, 2025
Association of edoxaban concentration with major bleeding in very elderly patients with atrial fibrillation treated by edoxaban 15 mg: A post-hoc analysis of ELDERCARE-AF trial
Poster
Edoxaban
EHRA 2025 | March 30-April 1, 2025
Comparative analysis of patient
characteristics and real-world outcomes
in Spanish patients with atrial fibrillation
treated with direct oral anticoagulants
versus vitamin K antagonists
Poster
Edoxaban
ISPOR 2025 | May 13-16, 2025
Comparative Effectiveness and Safety of Factor Xa Inhibitors in Atrial Fibrillation: A Systematic Literature Review of Real-World Evidence in Europe
Poster
Edoxaban
ISPOR EU 2024 | November 17-20, 2024
Examining real-world utilisation and associated clinical outcomes of direct oral anticoagulants (DOACs) in patients with atrial fibrillation in Italy
Poster
Edoxaban
EHRA 2025 | March 30-April 1, 2025
Real-world use and clinical outcomes among patients with atrial fibrillation using low-dose edoxaban and apixaban in Italy